>
Switch to:

Altamira Therapeutics Equity-to-Asset

: 0.85 (As of Jun. 2021)
View and export this data going back to 2014. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Altamira Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $22.13 Mil. Altamira Therapeutics's Total Assets for the quarter that ended in Jun. 2021 was $26.15 Mil.

The historical rank and industry rank for Altamira Therapeutics's Equity-to-Asset or its related term are showing as below:

NAS:CYTO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.48   Med: 0.76   Max: 1.49
Current: 0.85

-0.48
1.49

During the past 10 years, the highest Equity to Asset Ratio of Altamira Therapeutics was 1.49. The lowest was -0.48. And the median was 0.76.

NAS:CYTO's Equity-to-Asset is ranked lower than
99.99% of the 255 Companies
in the Biotechnology industry.

( Industry Median: 0.64 vs. NAS:CYTO: 0.85 )

Altamira Therapeutics Equity-to-Asset Historical Data

The historical data trend for Altamira Therapeutics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 -0.12 0.37 0.65 0.81

Altamira Therapeutics Semi-Annual Data
Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.65 0.56 0.81 0.85

Competitive Comparison

For the Biotechnology subindustry, Altamira Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Altamira Therapeutics Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Altamira Therapeutics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Altamira Therapeutics's Equity-to-Asset falls into.



Altamira Therapeutics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Altamira Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Equity to Asset (A: Dec. 2020 )=Total Stockholders Equity/Total Assets
=18.876632147681/23.411751463305
=0.81

Altamira Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2021 is calculated as

Equity to Asset (Q: Jun. 2021 )=Total Stockholders Equity/Total Assets
=22.127120511126/26.145626790042
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Altamira Therapeutics  (NAS:CYTO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Altamira Therapeutics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Altamira Therapeutics Business Description

Altamira Therapeutics logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
8 The Green, Suite 12455, Dover, DE, USA, 19901
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)